<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01222793</url>
  </required_header>
  <id_info>
    <org_study_id>999910460</org_study_id>
    <secondary_id>10-DA-N460</secondary_id>
    <nct_id>NCT01222793</nct_id>
  </id_info>
  <brief_title>Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia</brief_title>
  <official_title>Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

      - Although second-generation antipsychotic medications have fewer serious side effects and
      complications than first-generation ones, they are strongly associated with weight gain for
      reasons that are as yet unknown. Comparing the effects of second-generation antipsychotics
      with a high weight-gain liability (HWGL) low weight-gain liability (LWGL) antipsychotics may
      provide more information on which medications are best suited for different individuals.
      Researchers are interested in studying how people taking various antipsychotics compare with
      controls in regard to food craving and eating behavior. This knowledge should help to guide
      practitioners when advising patients about the weight-gain effects of these medications.

      Objectives:

      - To examine eating behavior and food craving in patients with schizophrenia who are taking
      HWGL antipsychotics compared with those taking LWGL antipsychotics and with healthy controls
      taking no antipsychotics.

      Eligibility:

        -  Individuals between 18 and 45 years of age who have been diagnosed with schizophrenia or
           a related disorder, have a body mass index between 25 and 29.9, and have never had an
           eating disorder.

        -  Healthy individuals between 18 and 45 years of age who have a body mass index between 25
           and 29.9 and have never had an eating disorder.

      Design:

        -  This study involves an initial screening visit and four study visits.

        -  Participants will be screened with a medical history and physical examination, as well
           as questionnaires about stress levels, food cravings, smoking, exercise, and eating
           habits; a taste test; and saliva collection (to measure stress hormones).

        -  Visit 2: Participants will have an optional overnight stay, and will provide blood
           samples before having a breakfast beverage and answering questions about tiredness,
           anxiety, hunger, and alertness during a 1.5 hour session.

      Visit 3: Participants will have an optional overnight stay and a light breakfast, followed by
      blood draws and questions about hunger and food cravings.

      Visit 4: Participants will have an optional overnight stay, followed by questions about food
      preference. Participants will not be allowed to eat until mid-morning of the next day.

      Visit 5: Participants will eat normally before arriving at the research site, and will have
      tests to measure food craving and questionnaires about mood and feelings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective

      Some second-generation antipsychotics, such as olanzapine and clozapine, seem especially
      prone to induce metabolic complications and substantial increases in weight. The mechanisms
      of these side effects are unknown, but may include antagonism at histamine H1 receptors. We
      will refer to olanzapine and clozapine as antipsychotics with a high weight-gain liability
      (HWGL). The primary aim of this project is to examine eating and food craving in patients
      with schizophrenia who are taking HWGL antipsychotics compared with those taking LWGL
      antipsychotics (mid- to high-potency first-generation antipsychotics, aripiprazole, or
      ziparasidone) and compared with healthy controls taking no antipsychotics. The antipsychotics
      we are classifying as LWGL group do not have appreciable H1 receptor antagonism. We will
      exclude participants taking antipsychotics that have middling degrees of H1 receptor
      antagonism (e.g. quetiapine).

      This study will help us understand how people with schizophrenia differ from controls on
      eating and food craving, as well as the effects of different classes of antipsychotics. This
      knowledge should help to guide practitioners when advising patients about the weight-gain
      effects of these medications. For example, if we find that participants on HWGL
      antipsychotics tend to crave high-fat foods, practitioners can work with patients to
      anticipate and mitigate this side effect.

      Study population. The study population will be in- or outpatients with a DSM-IV diagnosis of
      schizophrenia or schizoaffective disorder stabilized on either olanzapine or clozapine (HWGL
      antipsychotics) (N=20), aripiprazole, ziprasidone, or a first-generation antipsychotic (LWGL
      antipsychotics) (n=20), and normal controls (people with no Axis I psychiatric disorder
      taking no antipsychotic medication) (n=20), for a total of 60 participants. All participants
      will be between the ages of 18 to 45 years and considered overweight (BMI greater than or
      equal to 25 and less than or equal to 29.9 kg/m(SqrRoot)). The pediatric population has been
      excluded to rule out certain hormonal effects (e.g. puberty) on eating behavior. A BMI range
      encompassing participants that are overweight was selected to maximize recruitment and to
      minimize confounding effects of BMI on eating behavior. Exclusion criteria will include
      weight-related conditions and current dietary restrictions.

      Experimental design and methods. In a between-subjects design, the three study groups will be
      compared in terms of four domains of eating behavior: (1) food craving, (2) satiety
      signaling, (3) meal size (satiation), and (4) food preferences. Assessments will occur during
      five study visits (including an initial visit for consenting and screening).

      Outcome measures: Primary outcome measures will include a preload-test meal paradigm
      (satiety), meal size perception and satiation, food preference, food craving, and gustatory
      functioning. Secondary measures will include: Weight and Eating Assessment questionnaire,
      Recent Physical Activity Questionnaire (RPAQ), State Trait Anxiety Inventory (STAI), Exercise
      Motivations Inventory (EMI), Childhood Trauma Questionnaire, Tobacco Craving
      Questionnaire-Short Form (TCQ-SF), Fagerstrom Test for Nicotine Dependence (FTND), BMI,
      hip/waist measurements, and fasting blood work: CBC, CMP14, lipid panel, leptin, ghrelin,
      adiponectin, and thyroid panel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 26, 2010</start_date>
  <completion_date>May 3, 2012</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Obesity</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        All participants must:

          -  be between age 18 and 45.

          -  have a BMI between 25 or above.

        Participants in the antipsychotic-medication groups must:

        1. meet DSM-IV criteria for schizophrenia or schizoaffective disorder, and have been
        stabilized on an antipsychotic medication for the past 3 months. Antipsychotics include
        olanzapine, clozapine, aripiprazole, ziprasidone, and first-generation antipsychotics (mid
        to high potency). Polypharmacy is allowed as long as both medications fit into the same
        grouping (HWGL or LWGL).

        Healthy controls must:

        1. have no DSM IV Axis I disorder (Schizophrenia or schizoaffective disorder, Depression,
        Bipolar Disorder) based on a SCID interview.

        EXCLUSION CRITERIA:

        Participants will be excluded if they:

        meet DSM-IV criteria for a past and/or current eating disorder via the SCID, or if they
        have a past medical history of an eating disorder, received treatment/counseling for an
        eating disorder and/or required hospitalization for an eating disorder. (If an otherwise
        undiagnosed eating disorder is detected during screening, referral to treatment will be
        provided.)

        are taking risperidone, quetiapine, paliperidone, iloperidone, or low-potency
        first-generation antipsychotics (see Appendix A for complete list of excluded medications).

        are taking weight-loss medications, whether over-the-counter (i.e. Hydroxycut, Stacker
        products, Metabo-Plus, CortiSlim), or prescribed, including appetite suppressants (Didrex,
        Tenuate, Sanorex, Mazanor, Adipex-P, Meridia, and Phentermine) and fat-absorption
        inhibitors (Xenical).

        are currently enrolled in a nutrition-based weight-loss program (i.e. Weight Watchers,
        Jenny Craig, Nutri-System).

        have undergone weight-loss surgery (i.e. banding, gastric bypass surgery, sleeve
        gastrectomy, liposuction).

        have Cushing's syndrome, polycystic-ovary syndrome, hyperthyroidism, hypothyroidism, or a
        DSM-IV diagnosis of depression.

        have Type I or Type II diabetes, defined as a fasting blood glucose level of greater than
        or equal to 99.

        have cognitive impairment severe enough to preclude informed consent or valid responses on
        questionnaires. This is defined an as a score of less than 10 on the Evaluation to Sign
        Consent (ESC) and judged by the treating clinician. Participants obtaining a 10 on the ESC
        are re-briefed on the item that they missed, and are asked the question again until they
        get it correct to ensure their understanding.

        have a medical illness that, in the view of the investigators, would compromise
        participation.

        have dietary restrictions or food allergies that, in the view of the investigators, would
        compromise participation.

        are pregnant (as this might alter appetite or cravings).

        have begun or stopped smoking in the previous 3 months

        Also, participants will be excluded from the control group if they:

        are taking antipsychotics, antidepressants or mood stabilizers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol Myers, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Drug Abuse (NIDA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-1595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993 Dec;(22):39-44.</citation>
    <PMID>8110442</PMID>
  </reference>
  <reference>
    <citation>Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982 Jul;39(7):784-8.</citation>
    <PMID>7165477</PMID>
  </reference>
  <reference>
    <citation>Baptista T, De Mendoza S, Beaulieu S, Berm√∫dez A, Martinez M. The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management. Metab Syndr Relat Disord. 2004 Fall;2(4):290-307. doi: 10.1089/met.2004.2.290.</citation>
    <PMID>18370698</PMID>
  </reference>
  <verification_date>May 3, 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <keyword>High Weight Gain Liability (HWLA)</keyword>
  <keyword>Antipsychotic</keyword>
  <keyword>Obesity</keyword>
  <keyword>Low Weight Gain</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Food Craving</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

